Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $14 to $11.
Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $14 to $11.